$GALT Of the NASH drugs to watch listed by Benzinga, I believe GALT has the best potential The current “ leader” is plagued by FGF/FGFR tumorogenic concerns. ( Oncology is now actively targeting that pathway ) See trials ( PROOF trial, pan FGFR inhibitor, ongoing for cholangiocarcinoma, )this is no longer “ theoretical ”
  • 7
  • 4